Prime Highlights
- Evaro announced a partnership with U-Test Diagnostics to provide seamless at-home testing, prescription approvals, and next-day medication delivery across the UK.
- The platform enables secure online consultations without appointments or video calls, enhancing efficiency and accessibility in home healthcare.
Key Facts
- Evaro is NHS-licensed since 2018, holds CQC and GPhC certifications, and integrates with GP records to support safer prescribing decisions.
- The company recently closed a $25 million funding round to scale its home testing and healthcare service model, having supplied over 75 million lateral flow kits worldwide in the past five years.
Background
Evaro, a Norfolk-based NHS-licensed digital healthcare platform, has now announced a partnership with U-Test Diagnostics. The company offers customers a guide from diagnostic results to prescriptions in the entire UK. This partnership will provide a connecting link for public welfare, for those who are comfortable testing at home.
The platform manages the entire at-home testing process, guided by NHS-registered clinicians. They also provide prescription approvals and next-day medication delivery in almost all cases.
There’s also a huge welcoming perspective for the adoption of Home Testing, as the 2024 parliamentary report highlighted that there was an increase in public comfort for self-testing after COVID-19.
Evaro is licensed by the Care Quality Commission (CQC) and General Pharmaceutical Council (GPhC) and has NHS integration for safe prescribing.
The system efficiency allows the patients to complete secure online consultations without appointments or video calls, which enables efficiency in the medical treatment.
The company has 15 years and has also supplied more than 75 million lateral flow kits to the entire world in the past five years.
The company noted, “Partnering with Evaro helped us build a bridge for home testing and treatment”. Reports also said that last month, Evaro closed a $25 million series serving a funding to help scale its healthcare service model.
